Outcomes of lung cancers manifesting as nonsolid nodules

•Lung cancers manifesting as NSNs do not metastasize to LNs or other organs.•Approximately 70% of resected NSN cancers are AIS or MIA.•All Stage I adenocarcinomas with 100% long-term lung-cancer specific survival.•NSNs still need to be follow-up annually for development of a solid component.•Can be...

Full description

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 97; pp. 35 - 42
Main Authors Yip, Rowena, Wolf, Andrea, Tam, Kathleen, Taioli, Emanuela, Olkin, Ingram, Flores, Raja M., Yankelevitz, David F., Henschke, Claudia I.
Format Journal Article
LanguageEnglish
Published Ireland Elsevier Ireland Ltd 01.07.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•Lung cancers manifesting as NSNs do not metastasize to LNs or other organs.•Approximately 70% of resected NSN cancers are AIS or MIA.•All Stage I adenocarcinomas with 100% long-term lung-cancer specific survival.•NSNs still need to be follow-up annually for development of a solid component.•Can be followed for growth yearly as they are slow-growing cancers if diagnosed. This is a comprehensive review and re-analysis of available literature to assess the outcome of lung cancer presenting as nonsolid nodules (NSNs), a more indolent form of cancer. PubMed and EMBASE were searched for articles reporting on CT-detected lung cancers manifesting as NSNs published in English on or before July 17, 2015. Only studies including clinicopathologic data, lung cancer-specific survival, or overall survival were included. Data extraction was performed by three independent reviewers using prespecified criteria. Twenty-four articles from 5 countries met criteria and they included 704 subjects with 712 lung cancers manifesting as NSNs. Each article reported from 2 to 100 lung cancer cases with a median follow up of 18–51 months. All NSNs were Stage I adenocarcinoma without pathologic nodal involvement upon resection, except for one case in which the NSN progressed to become part-solid nodule after 6 years of follow-up. The five-year lung cancer-specific survival rate was 100%. These findings suggest an indolent course for lung cancers manifesting as NSNs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0169-5002
1872-8332
1872-8332
DOI:10.1016/j.lungcan.2016.04.005